Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2015, Article ID 563727, 5 pages
http://dx.doi.org/10.1155/2015/563727
Research Article

The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations

Department of Obstetrics and Gynecology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Received 10 June 2015; Accepted 11 October 2015

Academic Editor: Louise Hafner

Copyright © 2015 Elaine Duryea et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. CDC, “HIV in the United States: at a glance,” October 2014, http://www.cdc.gov/hiv/pdf/statistics_basics_factsheet.pdf.
  2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, “Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,” October 2014, http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
  3. K. Brinkman, H. J. M. Ter Hofstede, D. M. Burger, J. A. M. Smeitink, and P. P. Koopmans, “Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway,” AIDS, vol. 12, no. 14, pp. 1735–1744, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Ford, A. Calmy, I. Andrieux-Meyer, S. Hargreaves, E. J. Mills, and Z. Shubber, “Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis,” AIDS, vol. 27, no. 7, pp. 1135–1143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Bersoff-Matcha, W. C. Miller, J. A. Aberg et al., “Sex differences in nevirapine rash,” Clinical Infectious Diseases, vol. 32, no. 1, pp. 124–129, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Kontorinis and D. T. Dieterich, “Toxicity of non-nucleoside analogue reverse transcriptase inhibitors,” Seminars in Liver Disease, vol. 23, no. 2, pp. 173–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Cotter, A. G. Garcia, M. L. Duthely, B. Luke, and M. J. O'Sullivan, “Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?” Journal of Infectious Diseases, vol. 193, no. 9, pp. 1195–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. H. Watts, P. L. Williams, D. Kacanek et al., “Combination antiretroviral use and preterm birth,” The Journal of infectious diseases, vol. 207, no. 4, pp. 612–621, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. E. Tuomala, D. H. Watts, D. Li et al., “Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy,” Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 4, pp. 449–473, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. E. Tuomala, D. E. Shapiro, L. M. Mofenson et al., “Antiretroviral therapy during pregnancy and the risk of an adverse outcome,” The New England Journal of Medicine, vol. 346, no. 24, pp. 1863–1870, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. K. M. Powis, D. Kitch, A. Ogwu et al., “Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy,” Journal of Infectious Diseases, vol. 204, no. 4, pp. 506–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Sibiude, J. Warszawski, R. Tubiana et al., “Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?” Clinical Infectious Diseases, vol. 54, no. 9, pp. 1348–1360, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Papp, H. Mohammadi, M. R. Loutfy et al., “HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction,” Journal of Infectious Diseases, vol. 211, no. 1, pp. 10–18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. E. L. Duryea, J. S. Hawkins, D. D. McIntire, B. M. Casey, and K. J. Leveno, “A revised birth weight reference for the United States,” Obstetrics and Gynecology, vol. 124, no. 1, pp. 16–22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Schulte, K. Dominguez, T. Sukalac, B. Bohannon, and M. G. Fowler, “Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989–2004,” Pediatrics, vol. 119, no. 4, pp. e900–e906, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Martin, B. E. Hamilton, M. J. Osterman, S. C. Curtin, and T. J. Mathews, “Births: final data for 2012,” National Vital Statistics Reports, 2014, http://www.cdc.gov/nchs/data/nvsr/nvsr62/nvsr62_09.pdf. View at Google Scholar
  17. M. Ounsted, V. A. Moar, and A. Scott, “Risk factors associated with small-for-dates and large-for-dates infants,” British Journal of Obstetrics and Gynaecology, vol. 92, no. 3, pp. 226–232, 1985. View at Publisher · View at Google Scholar · View at Scopus
  18. H. S. Bada, A. Das, C. R. Bauer et al., “Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure,” Journal of Perinatology, vol. 25, no. 10, pp. 631–637, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. L. Bloom, N. P. Yost, D. D. McIntire, and K. J. Leveno, “Recurrence of preterm birth in singleton and twin pregnancies,” Obstetrics and Gynecology, vol. 98, no. 3, pp. 379–385, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults And Adolescents, Department of Health and Human Services, 2015, http://aidsinfo.nih.gov/contentfiles/adultandadolescentGL.pdf.